The U.S. Food and Drug Administration approved a 2 mg dose of Novo Nordisk’s Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
Patients with severe COVID-19 who develop diabetes while hospitalized may have only a temporary form of the disease and their blood sugar levels may return to normal afterward, according to new findings. Additionally, new data illustrate the jumps in U.S. coronavirus infection rates caused by the Omicron variant and the heavier toll it has taken on minorities in the latest example of racial disparity in the pandemic.
A smart insulin device under development could revolutionize how glucose levels are monitored in diabetes patients and deliver insulin doses when necessary.
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill approved by U.S. authorities that caters for patients with an aversion to needles.
The U.S. Food and Drug Administration approved Xeris Pharmaceuticals Inc.’s glucagon pen Gvoke, which aims to treat severely low sugar levels in diabetes patients.
AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.
Older adults with slightly elevated blood sugar – sometimes called “prediabetes” – usually do not develop full-blown diabetes, a Swedish study suggests.
